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Anal canal carcinoma is a rare gastro-intestinal cancer. Radiochemotherapy is the recommended primary
treatment for patients with non-metastatic carcinoma; surgery is generally reserved for persistent or recurrent
disease. Follow-up and surveillance after primary treatment is paramount to classify patients in those with
complete remission, persistent or progressive disease. Locally persistent disease represents a clinically significant
problem and its management remains subject of some controversy.
The aim of this systematic review is to summarise recommendations for the primary treatment of anal canal
carcinoma, to focus on the optimal time to consider residual disease as genuine persistence to proceed with
salvage treatment, and to discern how this analysis might inform future clinical trials in management in this
class of patients.Introduction
Carcinoma of the anal canal is a human papilloma virus
associated cancer affecting both men and women. It ac-
counts for only 2% of gastro-intestinal malignancies, but
its incidence has been increasing for the past 30 years,
with, in 2013, estimated worldwide new cancer cases of
7.060 in both sexes [1]. Despite the rarity of anal canal
cancer, it represents a successful model for the multi-
modality treatment in radiation oncology research.
Until the 1980s, surgery was the treatment of choice;
nowadays it is reserved for patients with persistent or re-
current disease. Due to superior local control and sur-
vival, and due to a better quality of life, prospective
randomized trials have established that the submission
of a combination of radiotherapy (RT) and chemother-
apy is the international standard of care for patients with
anal canal cancer [2-4]. Accurate tumour evaluation
after combined-modality therapy is thus essential for
prognostic information and for patient’s care. Questions
remain about the most effective management planning
after combined-modality therapy. Based on the results of
the ACT-II study [5], the NCCN guidelines recommended
a clinical observation – digital rectal exploration, inguinal
node palpation and anoscopy – as long as there is no* Correspondence: daniela.musio@libero.it
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unless otherwise stated.evidence of progressive disease [6]. Whereas, the Euro-
pean Society for Medical Oncology guidelines suggests
that MRI can be used to complement clinical assessment
in response evaluation [7]. In light of the difficulties in
obtaining clear recommendations, this review discusses
conceptual issues pertinent to anal carcinoma treatment,
with specific details in the management after primary
combined therapy.
Primary treatment of anal canal carcinoma
Since the pioneering work by Nigro et al. [8] in the
1974, the primary therapy of anal canal carcinoma has
shifted from radical surgery to combined radiochemo-
therapy (CRT), because of the chance of cure with a best
quality of life. Local excision could be considered for
small well-differentiated carcinomas of the anal margin
without evidence of sphincter involvement [7]. Random-
ized phase III trials have demonstrated the benefit of
CRT over RT alone, with a five-year disease free survival
in the range of 67–73% [2-4]. Radiation therapy plus
concurrent 5-fluorouracil (5-FU) and mitomycin C
(MMC) represents the preferred standard of care, due to
the clinically and statistically significant impact on sur-
vival, both overall and disease free [5,9]. No randomized
controlled trials have found a chemotherapy regimen
substantially more effective at improving local and dis-
tant control. Two randomized trials tested whether cis-
platin (CDDP) could be used instead of MMC, buttd. This is an Open Access article distributed under the terms of the Creative
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ACT I [2] 560 CRT vs RT LC; RFS; CFS; OS -
Intergroup [3] 310 CRT vs RT LC; CFS; OS; DFS -
EORTC [4] 110 CRT vs RT LC OS; CFS
UKCCCR [18] 856 CRT vs RT LC OS; morbidity
LC local control; RFS: relapse free survival, CFS colostomy free survival,
OS overall survival, DFS disease free survival.
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tinal Intergroup RTOG 98–11 trial data [10] did not show
a statistically significant difference in disease-free survival
between 320 patients who received RT with 5-FU plus
CDDP versus 324 patients submitted to 5-FU plus MMC
(60% vs 54%, p-value 0.17). Both colostomy-free survival
and overall survival were improved by CRT with MMC/5-
FU as compared to CRT with CDDP/5-FU (72% vs 65%
and 78% vs 71%, respectively). The ACT II [5] enrolled
940 patients randomly assigned to RT and concomitant
MMC/5-FU or CDDP/5-FU. Results reported no differ-
ence on progression-free survival between the two
chemotherapy strategies investigated (HR 0.95, 95% CI
0.75–1.19; p = 0.63), such as on overall survival and
colostomy-free survival (HR 1.05, 95% CI 0.80-1.38; p = 0.70;
and 73% vs 75%, respectively).
Nowadays, RT with 5-FU and MMC remains the stan-
dard practice in anal canal carcinoma, and, however it is a
rare situation, CDDP could be used in those patients in
which MMC is contraindicated.
Tumour regression
Tumour regression in defined as the total disappearance
of tumour with a normal anus mucosa [11]. The median
time to complete clinical regression after CRT is about 12
weeks (range 2 – 36 weeks) [12,13]. But tumour regres-
sion may be slower: some cancer could take up to 48
weeks to disappear [12], other to 72 weeks [14]. Although
the rapidity of the clinical response to therapy represents
a prognostic factor [11,15], these data confirmed that a
correct management after combined-modality therapy is
paramount.
Following primary treatment patients are re-evaluated.
Current guidelines include serial digital rectal exploration,
inguinal node palpation and anoscopy, with biopsy of
clinically evidence of progressive disease after CRT [6].
Lesions are classified according to their response in
complete regression, persistent disease or progressive
disease.
Clinical and imaging assessment of the radiation treated
field is often complicated by acute toxicity, such as mu-
cositis, that can persist for several weeks. In addition,
the clinical and imaging appearance of radiation reac-
tions can mimic persistent or recurrent disease. The ob-
vious limitation of clinical evaluation is the subjectivity
of the examination and the absence of treatment re-
sponse information for any deep and/or non-palpable
disease. But routine biopsy should not be performed,
because irradiated mucosa does not have the same abil-
ity to heal as normal mucosa and persisting discomfort,
like bleeding or proctitis, could be observed [5]. More-
over, pathologic interpretation of post-treatment biopsy
can be difficult due to significant treatment-related al-
terations [16].Therefore the timing of the identification of treatment
failure remains controversial. Patients who had not
achieved a rapid complete response to treatment could
benefit from a longer follow-up for tumour regression and
a salvage surgery can thereby be avoided. Currently an ar-
bitrary cut-off of 6 months after CRT is considered ad-
equate to accuracy of the biopsy and, consequently, to
distinguish patients with persistent disease from those with
complete response [17]. If no regression of disease is ob-
served by 6 months a salvage abdominal-perineal resection
should be considered [6]. But in several cases, the 6-month
window could be too early to allow for a complete tumour
response to occur [12,14]. Results from the UKCCCR ran-
domised trial showed that 77% of patients, who had not
complete tumour regression at the 6-week assessment,
achieved a complete response of primary tumour to CRT
treatment with longer follow-up [18]. Persistent disease
may continue to regress even at 26 weeks after the end of
CRT. In these cases, it is possible that patients are submit-
ted to abdominal-perineal resection but no cancer is found
on histopathological examination.
Previous literature has attempted to elucidate the better
treatment that may assure better rates of local control and
survival of patients with anal canal carcinoma. Rando-
mised phase III trials’ primary end-point was to demon-
strate the benefit of CRT over radiotherapy, evaluating
time to first loco-regional relapse (see Table 1). Most stud-
ies have attempted to define factors predictive of outcome
variables, such as age, tumour stage and response to ther-
apy [11,15]. Thus timing of tumour response was never
clearly defined. Randomised data reported the presence of
residual tumour evaluated within 6 weeks following the
end of treatment. It was considered as initial local failure
and a salvage surgery was proposed, but specific histo-
logical data are not available and it is difficult to argue if
an early intervention was performed.
Single institute retrospective analysis reported their
experience with salvage surgery after failed CRT therapy,
but time-details of biopsy or of clinical determination of
residual/persistent disease are not available [19-21].
The optimal time for surgical intervention remains un-
certain; avoidance of unnecessary overtreatment and ex-
cessive delay in treatment are both important, and an
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commonly used.
Response evaluation
Response evaluation after CRT represents a significant
problem and which is the optimal recommendation is still
debate. Traditionally response to CRT is assessed clinically,
because treatment related changes can cause difficulties in
response interpretation. As both endoanal ultrasound and
magnetic resonance imaging (MRI) play an established role
in the accurate locoregional staging of primary lesion, their
role in post-treatment evaluation is more debatable [22].
Response as defined by Response Evaluation Criteria in
Solid Tumours (RECIST criteria) at 6–8 weeks is a com-
monly employed end-point in phase II and phase III trials,
but it is useful only to achieve a predictive evaluation.
Oedema or scar tissue is difficult to distinguish from per-
sistent disease on endoanal ultrasound. Response evalu-
ation of treated disease with MRI can lead to false
persistent disease due to RT-related tumour fibrosis. Sev-
eral studies were proposed to establish the real prognostic
time to evaluate treatment response, but all are based on
small cohort of patients. Giovannini et al. [23] analyzed the
follow-up of 147 patients with anal canal disease after
CRT. They reported that 16–20 weeks after the end of
therapy represent a sufficient time to classify treatment re-
sponse by endoanal ultrasound, due to resolution of
oedema. In Tarantino et al. study [24] 12 patients, with a
biopsy-proven squamous-cell anal carcinoma, were sub-
mitted to surgery or CRT after endoanal ultrasound evalu-
ation. In surgery group, pathological staging was correlated
with ultrasound clinical staging; while for CRT patients,
endoanal ultrasound was compared to local biopsies per-
formed two - four months after the end of treatment.
Ultrasound evaluations correlated with surgical and bi-
opsy findings. Authors concluded that endoanal ultra-
sound could be used to accurately determine the
response of the squamous-cell anal carcinoma to mul-
timodality therapy.
The high contrast resolution of pelvic MRI makes it
an ideal modality for response assessment, understand-
ing the pattern of tumour regression and monitoring
treatment response. However few data on optimal time
to perform MRI and to evaluate treatment response
are available [13]. Certainly MRI has a specific role in
the evaluation of recurrent disease following RT, con-
sidering its specific signal characteristic – high signal
intensity relative to skeletal muscle on T2-weighted
images, and low to intermediate signal intensity on T1-
weighted images – [25]. A stabilization of signal in-
tensity abnormality one year after the end of CRT may
indicate a treatment success. However this observation
needs to be verified in clinical studies with a great
number of patients [26].Metabolic and functional imaging techniques, such as
diffusion-weighted MRI (DW-MRI) or positron emission
tomography with F-18 fluorodeoxyglucose (FDG-PET),
should be used to assess therapeutic response, but fur-
ther studies are awaited to state stronger information.
DW-MRI may directly measure the changes in tumour
aggressiveness, evaluating tumour angiogenesis and cel-
lularity. The treatment response using DW parameter –
apparent diffusion coefficient (ADC) value – has been
shown to be predictive of early therapeutic response in a
large variety of tumours, including head and neck tu-
mours, pancreatic tumours, cervical tumours, and rectal
cancer, but its potentiality as imaging biomarker in anal
canal carcinoma is not still tested [27,28]. Pre- and post-
treatment ADC value should be considered to address
the use of DW-MRI as an alternative approach to the
management of persistent disease.
FDG-PET may potentially provide further information
of tumour glucose uptake, before and after cancer therapy.
Its utility in the pre-treatment evaluation of anal canal car-
cinoma is well documented [29,30] and the NCCN treat-
ment guidelines now consider FDG-PET an optional
diagnostic exam for staging primary disease [6]. Schwarz
et al. [16] evaluated the metabolic response to therapy
using FDG-PET, in 53 consecutive patients with anal
canal. Post-treatment FDG-PET was performed 0.9-
5.4 months (mean, 2.1; median, 2.0) after treatment: per-
sistent FDG uptake was confirmed as residual disease by
biopsy in 67% of patients. Additional post treatment stud-
ies are necessary to determine the optimal timing of post
FDG-PET evaluation, to reduce false-positive results.
MRI, with or without DW, and FDG-PET should be
performed if there is a clinical suspicion of disease per-
sistence, but advances in imaging are necessary to im-
prove medical decision making in the management of
anal cancer.
Future perspectives
The immediate future of research in anal canal carcin-
oma will be two-fold. One will be of diagnostic impact,
determining what combination of metabolic assays
(ADC, FDG-PET) is the most robust, sensitive and spe-
cific for residual disease after treatment. The second is
determining the biochemical and biological effects of
molecular inhibitors agents in tumour cells, in order to
validate targeted therapies for this carcinoma. There is
an opportunity for study of newer prognostic factor,
such as tumour-infiltrating lymphocytes, in attempt to
improve immunotherapeutic strategies [31]. No ongoing
trials explore the optimal timing to evaluate treatment
response in anal canal carcinoma.
The right identification of post-treatment response is
paramount to patient’s management and it should be
considered an hypotheses to test in a prospective trial.
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patients with a partial response to treatment. We have
evaluated the effect of CRT in 15 patients, with histologi-
cally proven anal squamous cell carcinoma, clinically
staged on anoscopy and whole body CT as T1 (2 patients),
T2 (9 patients), T3 (3 patients), T4 (1 patient); 5 patients
had positive lymph nodes. Response to CRT was assessed
clinically. In case of an uncertain evaluation, patients
underwent anoscopy and/or abdominal-pelvic MRI. Six
months after the end of treatment, all patients had digiatal
examination, anoscopy and whole body CT, as at baseline.
Discordance in response evaluation was noticed in 3 pa-
tients: negative clinical examination and positive imaging
results were found in 2 patients, positive digital examin-
ation and complete imaging response in 1 patient.
Abdominal-perineal resection was done and no tumour in
the operative specimen was found. These facts suggested
us the need for longer timing before surgical approach, to
potentiate the beneficial effect of CRT and to reduce im-
aging treatment artificial. We have begun to use a cut-off
of 8 months, in patients who had not achieved a rapid
complete response to CRT. Our experience is too re-
stricted to be considered a statement of evidence. Further
investigation in a larger number of patients is necessary.
Conclusions
A multidisciplinary approach is necessary in patients
with anal canal carcinoma. The curative potential role of
CRT is well documented. Follow-up clinical evaluations
are recommended, but decision to base the management
of persistent anal canal carcinoma after combined-
modality therapy is not clearly progressing. Recent find-
ings indicate that a complete clinical response occurs in
the majority of patients, within 6-month the end of
CRT. Patients with evidence of persistent disease with-
out proven loco-regional progression should benefit
from a close follow-up to evaluate if tumour regression
occurs.
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